Evolus (EOLS) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued twelve-month price objectives for Evolus' shares. Their EOLS share price forecasts range from $18.00 to $27.00. On average, they predict the company's stock price to reach $21.40 in the next year. This suggests a possible upside of 132.9% from the stock's current price.
View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts.

Evolus' stock was trading at $7.51 at the beginning of 2023. Since then, EOLS shares have increased by 22.4% and is now trading at $9.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our EOLS earnings forecast.

Evolus, Inc. (NASDAQ:EOLS) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The company earned $49.35 million during the quarter, compared to analysts' expectations of $46.12 million. Evolus had a negative trailing twelve-month return on equity of 507.42% and a negative net margin of 39.36%.

Evolus updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $185.00 million-$195.00 million, compared to the consensus revenue estimate of $187.83 million.

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Organigram (OGI) and Bionano Genomics (BNGO).

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus' stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (7.91%), BlackRock Inc. (5.26%), Great Point Partners LLC (4.27%), Schroder Investment Management Group (2.87%), Boothbay Fund Management LLC (2.29%) and Marshall Wace LLP (1.82%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar, Sandra Beaver and Vikram Malik.
View institutional ownership trends.

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EOLS stock can currently be purchased for approximately $9.19.

Evolus (NASDAQ:EOLS) has a market capitalization of $523.55 million and generates $148.62 million in revenue each year. The company earns $-74,410,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis.

The company employs 215 workers across the globe.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com.